Prediagnostic circulating 25-hydroxyvitamin D and prostate cancer-specific survival: a collaborative pooled analysis of 13 prospective studies
Abstract
Background: Previous research suggests higher risk of prostate cancer diagnosis in men with high vitamin D serology, but there are limited data related to prostate cancer survival. In this study, we examine the associations between prediagnostic circulating levels of 25-hydroxyvitamin D [25(OH)D] with risk of prostate cancer-specific mortality, as well as mortality from other causes, in participants diagnosed with prostate cancer.
Methods: We conducted a prospective multi-national collaborative analysis of pre-diagnostic circulating 25(OH)D, the major biochemical indicator of vitamin D status, with data for 12,635 incident prostate cancer cases from 13 cohorts. Multivariable-adjusted Cox proportional hazards regression models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between study-specific/season-standardized categories as well as clinically defined 25(OH)D categories (<30, 30-<50, 50-<75, and ≥75 nmol/L) and mortality from prostate cancer and other causes.
Results: Analyses of circulating 25(OH)D and mortality were based on 3,445 deaths, of which 1,316 (38.2%) were due to prostate cancer. In fully adjusted models, men with high pre-diagnostic 25(OH)D concentrations experienced lower prostate cancer-specific mortality (HR for 80-percentile increase = 0.75, 95% CI: 0.64, 0.88; Ptrend < 0.001) and slightly lower risk of mortality from other causes (HR = 0.85, 95% CI: 0.75, 0.96, Ptrend = 0.009). In the subset of cases with complete stage and grade data (5,078 cases [40.2%] and 761 deaths from prostate cancer [57.8%]), the association between 25(OH)D and prostate cancer mortality was 0.81 (0.65, 0.99, Ptrend=0.04).
Conclusions: In this pooled analysis of 13 prospective cohorts, higher pre-diagnostic circulating vitamin D (25(OH)D) was associated with increased prostate cancer survival.
The Di Bella's Method: Use of Vitamin D, Melatonin (since 1974), Somatostatin/Octreotide analogues and/or derivatives (since 1977), Retinoic Acid, Beta-Carotene and Axerophthol palmitate, Hormone therapy (e.g. Enantone, Decapeptyl and analogues), pseudo-Metronomic Chemotherapy Cyclophosphamide and/or Hydroxyurea with prolactin inhibitors Cabergoline and/or Bromocriptine (together with others chemical compounds) in Prostate Cancer (the dosage and administration schedule must be individualised for each patient):
- Disease Control after Androgen Deprivation Therapy Combined with Di Bella Multitherapy;
See also:
- Official Web Site: The Di Bella Method;
- Vitamin D (analogues and/or derivatives) and cancer - In vitro, review and in vivo publications;
- Solution of retinoids in vitamin E in the Di Bella Method biological multitherapy;
- 2015 Dec - Publication: Solution of retinoids in vitamin E in the Di Bella Method biological multitherapy (from Di Bella's Foundation);
- Beta-Carotene or β-carotene in Solution of retinoids in vitamin E in the Di Bella Method biological multitherapy;
- The Di Bella Method (A Variable Part - Selenium methonine, 40 μg capsules, twice a day);
- The Di Bella Method (A Fixed Part - Calcium, 2 grams per day, orally);
- Somatostatin in oncology, the overlooked evidences - In vitro, review and in vivo publications;
- Publication, 2018 Jul: Over-Expression of GH/GHR in Breast Cancer and Oncosuppressor Role of Somatostatin as a Physiological Inhibitor (from Di Bella's Foundation);
- Publication, 2018 Sep: The over-expression of GH/GHR in tumour tissues with respect to healthy ones confirms its oncogenic role and the consequent oncosuppressor role of its physiological inhibitor, somatostatin: a review of the literature (from Di Bella's Foundation);
- Publication, 2019 Aug: The Entrapment of Somatostatin in a Lipid Formulation: Retarded Release and Free Radical Reactivity (from Di Bella's Foundation);
- Publication, 2019 Sep: Effects of Somatostatin and Vitamin C on the Fatty Acid Profile of Breast Cancer Cell Membranes (from Di Bella's Foundation);
- Publication, 2019 Sep: Effects of somatostatin, curcumin, and quercetin on the fatty acid profile of breast cancer cell membranes (from Di Bella's Foundation);
- Publication, 2020 Sep: Two neuroendocrine G protein-coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives (from Di Bella's Foundation);
- The Di Bella Method (A Fixed Part - Bromocriptine and/or Cabergoline);
- Prolactin inhibitors in oncology - In vitro, review and in vivo publications;
The Di Bella's Method: Use of Vitamin D analogues and/or derivatives - together with others chemical compounds: the dosage and administration schedule must be individualised for each patient - in several Oncological Pathologies:
- Complete objective response to biological therapy of plurifocal breast carcinoma;
- Pleural Mesothelioma: clinical records on 11 patients treated with Di Bella's Method;
- Malignant pleural mesothelioma, stage T3-T4. Consideration of a case study;
- Neuroblastoma: Complete objective response to biological treatment;
- Large B-cells Non-Hodgkin's Lymphoma, Stage IV-AE: a Case Report;
- Non-Hodgkin's Lymphoma, Stage III-B-E: a Case Report;
- Oesophageal squamocellular carcinoma: a complete and objective response;
- Pancreatic Adenocarcinoma: clinical records on 17 patients treated with Di Bella's Method;






